fMRI hints 'will' and 'grace' are not equally honest
Honest people tell the truth, even when given a chance to lie, as shown in an fMRI brain study of truth telling and prevarication from Harvard behavioral scientists.
Honest people tell the truth, even when given a chance to lie, as shown in an fMRI brain study of truth telling and prevarication from Harvard behavioral scientists.
The group, led by Joshua Greene, an assistant professor of psychology at Harvard, assessed 35 subjects who attempted to predict random coin flip outcomes while undergoing fMRI. Rewarded for accuracy and punished for inaccuracy, the study design also allowed them to cheat. Researchers found honest individuals displayed little to no additional neural activity in control-related brain regions when telling the truth, but liars did. Prevailing theories behind lie detection, “will” and “grace,” hypothesize that honesty results either from an active resistance to temptation or from a lack of response to it. Study findings lean toward the latter, according to researchers (Proc Natl Acad Sci USA 2009).
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
